TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer Monitoring℠ platform will be presented at …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock. …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced that it is offering to sell shares of its common stock in an …
In a research report issued today, Cantor analyst Sung Ji Nam reiterated a Buy rating on TrovaGene Inc (NASDAQ:TROV) with an $8 price target, after several …
